Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease

[1]  I. Ferrer,et al.  Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain , 2015, Journal of neurochemistry.

[2]  A. Tobeña,et al.  Cognitive and emotional alterations in young Alzheimer's disease (3xTgAD) mice: Effects of neonatal handling stimulation and sexual dimorphism , 2015, Behavioural Brain Research.

[3]  A. Tobeña,et al.  Cognitive and emotional profiles of aged Alzheimer's disease (3×TgAD) mice: Effects of environmental enrichment and sexual dimorphism , 2014, Behavioural Brain Research.

[4]  J. Laitinen,et al.  Lipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradation , 2012, BMC pharmacology.

[5]  M. Delgado,et al.  Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice , 2012, Journal of Neuroinflammation.

[6]  E. Mufson,et al.  Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice , 2011, Neurobiology of Disease.

[7]  C. Fowler,et al.  Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity? , 2010, Experimental Neurology.

[8]  K. Bromley-Brits,et al.  Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. , 2010, Current Alzheimer research.

[9]  F. LaFerla,et al.  Intraneuronal β-Amyloid Accumulation in the Amygdala Enhances Fear and Anxiety in Alzheimer's Disease Transgenic Mice , 2010, Biological Psychiatry.

[10]  W. Bowers,et al.  Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice , 2008, BMC Neuroscience.

[11]  K. Welsh-Bohmer.  Defining “Prodromal” Alzheimer’s Disease, Frontotemporal Dementia, and Lewy Body Dementia: Are we There Yet? , 2008, Neuropsychology Review.

[12]  J. Laitinen,et al.  Neuroanatomical mapping of juvenile rat brain regions with prominent basal signal in [35S]GTPγS autoradiography , 2008, Journal of Chemical Neuroanatomy.

[13]  F. LaFerla,et al.  Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid , 2007, Neuroscience & Biobehavioral Reviews.

[14]  C. Beyer,et al.  Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon , 2007, Neuropeptides.

[15]  S. DeKosky,et al.  Cholinergic forebrain degeneration in the APPswe/PS1ΔE9 transgenic mouse , 2007, Neurobiology of Disease.

[16]  Peter Bailey.  Biological Markers in Alzheimer's Disease , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  M. Giovannini,et al.  Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice , 2006, Neurobiology of Disease.

[18]  L. Descarries,et al.  Cholinergic modulation of cortical activity , 2006 .

[19]  E. Mufson,et al.  Galanin plasticity in the cholinergic basal forebrain in Alzheimer’s disease and transgenic mice , 2005, Neuropeptides.

[20]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[21]  J. Traynor,et al.  The [35S]GTPγS binding assay: approaches and applications in pharmacology , 2003 .

[22]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[23]  F. Drago,et al.  Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. , 2003, European journal of pharmacology.

[24]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[25]  D. Mash,et al.  Galanin receptor over-expression within the amygdala in early Alzheimer's disease: An in vitro autoradiographic analysis , 2002, Journal of Chemical Neuroanatomy.

[26]  J. Guimón,et al.  Effects of Age, Postmortem Delay and Storage Time on Receptor-mediated Activation of G-proteins in Human Brain , 2002, Neuropsychopharmacology.

[27]  M. Palkovits,et al.  Stress-induced expression of co-localized neuropeptides in hypothalamic and amygdaloid neurons. , 2000, European journal of pharmacology.

[28]  T. Hökfelt,et al.  Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F β-amyloid precursor protein — initial observations , 2000, Neuroscience.

[29]  D. Mash,et al.  Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis , 2000, Neuropharmacology.

[30]  M. Heilig,et al.  Anxiogenic-Like Action of Galanin after Intra-Amygdala Administration in the Rat , 1999, Neuropsychopharmacology.

[31]  G. Kinney,et al.  Galanin Receptor-Mediated Inhibition of Glutamate Release in the Arcuate Nucleus of the Hypothalamus , 1998, The Journal of Neuroscience.

[32]  W. Klunk.  Biological Markers of Alzheimer’s Disease , 1998, Neurobiology of Aging.

[33]  Y. Kubota,et al.  GABAergic cell subtypes and their synaptic connections in rat frontal cortex. , 1997, Cerebral cortex.

[34]  Á. Pazos,et al.  Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease , 1997, Synapse.

[35]  T. Hökfelt,et al.  125I‐Galanin Binding Sites in Alzheimer's Disease: Increases in Hippocampal Subfields and a Decrease in the Caudate Nucleus , 1997, Journal of neurochemistry.

[36]  M. Herkenham,et al.  Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.

[37]  M. Heilig,et al.  Anxiolytic-like action of centrally administered galanin , 1993, Neuroscience Letters.

[38]  V. Chan‐Palay.  Galanin hyperinnervates surviving neurons of the human basal nucleus of meynert in dementias of alzheimer's and parkinson's disease: A hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia , 1988, The Journal of comparative neurology.

[39]  D. Neary,et al.  Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease , 1987, Journal of neurochemistry.

[40]  P. Yates,et al.  The topography of cell loss from locus caeruleus in Alzheimer's disease , 1986, Journal of the Neurological Sciences.

[41]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[42]  I. Ferrer,et al.  Type-1 cannabinoid receptor activity during Alzheimer's disease progression. , 2014, Journal of Alzheimer's disease : JAD.

[43]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[44]  I. Ferrer,et al.  CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. , 2013, Journal of Alzheimer's disease : JAD.

[45]  F. LaFerla,et al.  Early increases in soluble amyloid-β levels coincide with cholinergic degeneration in 3xTg-AD mice. , 2012, Journal of Alzheimer's disease : JAD.

[46]  S. DeKosky,et al.  Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. , 2007, Neurobiology of disease.